signed an agreement with Pfizer and BioNTech to supply the South American country with 9.9 million doses of its BNT162b2 vaccine candidate, once it is approved.
"Currently, a phase 3 clinical study is underway in the United States, Germany, Argentina, Turkey and South Africa, in order to verify the effectiveness of the vaccine candidate," the
Ministry of Foreign Affairs said in a press release.
The BNT162b2 vaccine candidate —under the evaluation regimen of two doses of 30 µg— has been developed using a technological platform of messenger ribonucleic acid (mRNA).
In this regard, Erika Pagani, general manager of Pfizer Peru, Ecuador and Bolivia, said that they feel deeply honored to work with the Government of Peru and to direct their scientific and production resources towards a common goal, providing Peruvians with a potential vaccine against COVID-19 as quickly as possible.